An immune-related adverse event of Behcet’s-like syndrome following pembrolizumab treatment
Abstract Background In recent years, the emergence of immunotherapy has renewed therapeutic modality. Different from traditional anti-tumor therapy, immune-related adverse events of skin, gastrointestinal tract, liver, lung, endocrine glands commonly occurred. At present, only one case of immune-rel...
Main Authors: | Qiao Chen, Deyu Li, Guifeng Zhang, Jiangming Zhong, Li Lin, Zhenhua Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-04-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12890-024-02986-y |
Similar Items
-
Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients
by: Anne Schaefer, et al.
Published: (2020-04-01) -
Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer
by: Blaine Brower, et al.
Published: (2024-04-01) -
Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review
by: Chongya Zhai, et al.
Published: (2024-01-01) -
Bilateral optic neuritis attributed to Pembrolizumab: A case report
by: Dr Lucy G Faulkner, et al.
Published: (2024-03-01) -
Durable complete remission after Pembrolizumab in pretreated advanced endometrial cancer: A case report
by: Nicoletta Provinciali, et al.
Published: (2022-09-01)